In this article
Eli Lilly
on Thursday reported first-quarter earnings and revenue that blew past estimates and hiked its full-year sales outlook by $2 billion, as demand for its blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro spiked again.
The pharmaceutical giant now expects 2026 revenue to come in between $82 billion and $85 billion, up from a previous guidance of $80 billion to $83 billion.
Lilly also expects its full-year adjusted profit to be between $35.50 to $37 per share. That compares to a previous outlook of $33.50 to $35 per share.
